Cosmos

Cosmos is a dataset created in collaboration with a community of health systems using Epic and is designed to improve patient care. By combining their data, participating organizations and Epic can make new discoveries and advance medicine. Cosmos also powers tools at the point of care, providing insights to clinicians that are tailored to the patient in front of them.
More about Cosmos →

Cosmos Community

1,614
Hospitals
284 Million
Patients
36.9K
Clinics
Meet a few of our Cosmos community members:
AltaMed
OrthoVirginia
Penn Medicine
Loma Linda University Medical Center
Contra Costa Health
University of Arkansas for Medical Sciences
WakeMed Health and Hospitals
Wellstar
Learn more about the Cosmos community →

Cosmos in Action

Cosmos at the Point of Care

The vision for Cosmos has always included empowering providers with data to improve care for their patients. With our recently released and ongoing development of Cosmos-enabled features, providers can use attributes from the patient in front of them to review personalized insights they can use alongside their own expertise and experience to partner with their patient on shared decision-making. Some examples include:

Best Care Choices

To further evidence-based care, Best Care Choices for My Patient shows providers insights into how similar patients responded to the treatments they are considering, right at the point of care. Physicians will be able to explore the collective knowledge from millions of clinical decisions to see treatments and resulting outcomes for patients like the one in front of them.

Look-Alikes

Very rare conditions and medical mysteries often result in limited evidence for a physician to draw from when determining a course of action or treatment for their patient. Look-Alikes enables providers to connect with other providers across the Cosmos community who might have experience with patients with a similar constellation of symptoms or condition so they can collaborate on care.

Condition-Specific Growth Charts

Standard growth charts often don't account for disease-specific nuances that can influence a child's development. When a chronic condition affects a child’s growth, Cosmos enables growth charts that show clinicians and family members how the child is progressing relative to others with the same disease.

Publications Using Cosmos

Researchers in the Cosmos community have published dozens of papers using Cosmos data. Below are several examples of publications that used Cosmos data as part of their analysis.

Epic Research

While traditional research continues to serve as a primary source of information to inform clinical practice, we identified a need for a new kind of analysis focused on getting good data out quickly to clinicians and decision-makers where it can make a difference. To address this need, we launched Epic Research. Using our dual-team process, Epic Research teams evaluate timely, topical, and relevant questions and make findings available to the public at no-cost at EpicResearch.org.
Likelihood of Anxiety by Birth Order

Firstborn Children and Only Children More Likely to Have Anxiety and Depression Than Later-Born Children

Firstborn children who have siblings are 48% more likely to have anxiety and 35% more likely to have depression compared to children who are born second or later. 

Read the full brief on Epic Research →
Proportion of Emergency Encounters with Self-Pay Coverage by Age Group

Uninsured Emergency Visits on the Rise Since the End of Medicaid Continuous Enrollment

Self-pay emergency visits are on the rise in all age groups since the end of Medicaid continuous enrollment. 

Read the full brief on Epic Research →
Proportion of Patients by Weight Change After Stopping Semaglutide

Many Patients Maintain Weight Loss a Year After Stopping Semaglutide and Liraglutide

More than half of patients are able to maintain weight loss achieved while on semaglutide or liraglutide even a year after discontinuing the medication.

Read the full brief on Epic Research →
Five-Year Likelihood of Dementia Diagnosis by Diabetes Medication

GLP-1 Medications Associated with Reduced Likelihood of Dementia Compared to Other Diabetic Meds

Patients with diabetes who are prescribed semaglutide, exenatide, liraglutide, or dulaglutide experience a 23–44% reduced likelihood of dementia compared to those prescribed other diabetes management medications.

Read the full brief on Epic Research →
Explore more studies and data insights from Cosmos
on Epic Research →
Copyright © Epic Systems Corporation 2024.
This page is not viewable using Internet Explorer. Please try accessing it with an alternate browser.